Clinical Activity of Daratumumab Monotherapy in Heavily Pretreated RRMM

Conference Correspondent  - TOP - ASH 2015 - Multiple Myeloma, Conference Correspondent

Usmani and colleagues reported on the results of a combined efficacy analysis of patients treated with the anti-CD38 monoclonal antibody daratumumab in 2 trials, Sirius and part 2 of GEN501 trials, of patients with relapsed/refractory multiple myeloma (RRMM).1 Sirius is a 2-part, randomized phase 2 study in patients who had received ≥3 prior therapies, including a proteasome inhibitor or immunomodulatory drug, or were refractory to both these drug classes. GEN501 is a 2-part (part 1, dose escalation; part 2, dose expansion) study in patients who had relapsed after or were refractory to ≥2 prior therapies. The study population included 148 patients; 42 patients were from the GEN501 trial and 106 were from the Sirius trial. In the combined analysis, patients achieved an objective response rate (ORR) of 31% and ≥very good partial response rate of 10%; 1% of patients achieved complete responses (CRs) and 2% achieved stringent CRs. At a median follow-up of 9.3 months, the median duration of response in the combined analysis was 7.6 months, and the 1-year progression-free survival was 46% among responders. At a median follow-up of 14.8 months, the estimated median overall survival (OS) was 19.9 months in the combined analysis; the estimated 1-year OS rate was 69%. The efficacy outcomes in the individual GEN501 trial were similar, the ORR was 36%, the estimated 1-year OS rate was 77%, and median OS had not been reached at a median follow-up of 10.2 months. In the Sirius trial, an ORR of 36% was reported, the estimated 1-year OS rate was 65%, and median OS had not been reached at median follow-up of 9.3 months. Overall, it was concluded that the results of the combined analysis supported the individual study results in demonstrating a robust clinical activity of daratumumab monotherapy in heavily pretreated patients with RRMM. Based primarily on these data, daratumumab monotherapy was approved on November 16, 2015, for the treatment of patients with MM who have received at least 3 prior treatments. Daratumumab is the first monoclonal antibody approved for the treatment of MM.

  1. Usmani S, et al. ASH 2015. Abstract 29.
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017